DK3190113T3 - Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist - Google Patents
Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist Download PDFInfo
- Publication number
- DK3190113T3 DK3190113T3 DK15831451.8T DK15831451T DK3190113T3 DK 3190113 T3 DK3190113 T3 DK 3190113T3 DK 15831451 T DK15831451 T DK 15831451T DK 3190113 T3 DK3190113 T3 DK 3190113T3
- Authority
- DK
- Denmark
- Prior art keywords
- compounds used
- tlr7 agonist
- pyrrolopyrimidine compounds
- pyrrolopyrimidine
- tlr7
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410405136.0A CN105367576A (zh) | 2014-08-15 | 2014-08-15 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
CN201510392499 | 2015-07-06 | ||
PCT/CN2015/086909 WO2016023511A1 (zh) | 2014-08-15 | 2015-08-14 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3190113T3 true DK3190113T3 (da) | 2021-06-07 |
Family
ID=55303885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15831451.8T DK3190113T3 (da) | 2014-08-15 | 2015-08-14 | Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist |
Country Status (26)
Country | Link |
---|---|
US (2) | US9962388B2 (da) |
EP (1) | EP3190113B1 (da) |
JP (2) | JP6328341B2 (da) |
KR (2) | KR102215609B1 (da) |
CN (4) | CN110938076B (da) |
AU (3) | AU2015303558B2 (da) |
BR (1) | BR112017002811B1 (da) |
CA (1) | CA2958097C (da) |
CL (1) | CL2017000379A1 (da) |
DK (1) | DK3190113T3 (da) |
EA (1) | EA032824B1 (da) |
ES (1) | ES2875313T3 (da) |
HR (1) | HRP20210927T1 (da) |
HU (1) | HUE054672T2 (da) |
IL (2) | IL250586B (da) |
LT (1) | LT3190113T (da) |
MX (1) | MX2017002028A (da) |
MY (1) | MY190026A (da) |
PH (2) | PH12017500281B1 (da) |
PL (1) | PL3190113T3 (da) |
PT (1) | PT3190113T (da) |
SG (2) | SG10201809918RA (da) |
SI (1) | SI3190113T1 (da) |
UA (1) | UA117634C2 (da) |
WO (1) | WO2016023511A1 (da) |
ZA (1) | ZA201803736B (da) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
CN110938076B (zh) * | 2014-08-15 | 2021-08-10 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
PL3294740T3 (pl) | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
KR102112192B1 (ko) * | 2015-11-05 | 2020-05-19 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Tlr7 효능제로서의 7-(티아졸-5-일)피롤로피리미딘 화합물 |
CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
CN107043377A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
JP2019525947A (ja) | 2016-06-01 | 2019-09-12 | エムスリー・バイオテクノロジー・インコーポレイテッドM3 Biotechnology, Inc. | 化合物 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
RU2751349C2 (ru) | 2016-08-29 | 2021-07-13 | Ф. Хоффманн-Ля Рош Аг | 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции |
PE20190732A1 (es) | 2016-09-09 | 2019-05-23 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
EP3512556B1 (en) | 2016-09-13 | 2021-08-18 | F. Hoffmann-La Roche AG | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
AU2017342536A1 (en) | 2016-10-14 | 2019-05-02 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome |
WO2018078149A1 (en) * | 2016-10-31 | 2018-05-03 | F. Hoffmann-La Roche Ag | Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
EP3539963A4 (en) | 2016-11-11 | 2020-05-13 | Hepo Pharmaceutical Co., Ltd. | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE |
AU2017366621B2 (en) * | 2016-11-28 | 2021-07-29 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof |
CN110177793B (zh) | 2017-05-18 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | 杂芳基并吡唑类衍生物、其制备方法及其在医药上的应用 |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
JP7265554B2 (ja) | 2017-11-14 | 2023-04-26 | ブリストル-マイヤーズ スクイブ カンパニー | 置換インドール化合物 |
SI3728252T1 (sl) * | 2017-12-18 | 2023-11-30 | Bristol-Myers Squibb Company | 4-azaindolne spojine |
ES2932361T3 (es) | 2017-12-19 | 2023-01-18 | Bristol Myers Squibb Co | Compuestos de indol sustituidos útiles como inhibidores de TLR |
JP7304352B2 (ja) | 2017-12-19 | 2023-07-06 | ブリストル-マイヤーズ スクイブ カンパニー | 6-アザインドール化合物 |
SG11202005700SA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Amide substituted indole compounds useful as tlr inhibitors |
ES2965182T3 (es) | 2017-12-20 | 2024-04-11 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con arilo y heteroarilo |
SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
KR20200100760A (ko) * | 2017-12-20 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | 디아자인돌 화합물 |
CN111699187A (zh) | 2018-02-12 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的砜化合物和衍生物 |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
KR20200140867A (ko) | 2018-04-06 | 2020-12-16 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
AU2019272478A1 (en) | 2018-05-25 | 2020-12-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
EP3865483A4 (en) * | 2018-10-12 | 2022-06-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 AGONIST FOR THE TREATMENT OF COLORECTAL CANCER AND PHARMACEUTICAL COMBINATION THEREOF |
MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
CN113747899B (zh) * | 2019-03-15 | 2023-11-21 | 正大天晴药业集团股份有限公司 | 用于治疗乙型肝炎的Toll样受体激动剂 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
CN113543788B (zh) | 2019-04-23 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的固体药物组合物 |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
CN112321590A (zh) | 2019-08-02 | 2021-02-05 | 百济神州有限公司 | 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂 |
EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
EP4029503A4 (en) * | 2019-09-29 | 2023-10-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | COMBINATION OF DRUGS CONTAINING A TLR7 AGONIST |
WO2021067181A1 (en) | 2019-09-30 | 2021-04-08 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
EP4097106A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
EP4097105A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
US20230140430A1 (en) | 2020-01-27 | 2023-05-04 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
US20230122249A1 (en) | 2020-01-27 | 2023-04-20 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
US20230130516A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
EP4097100A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
US20230144824A1 (en) | 2020-01-27 | 2023-05-11 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
WO2021154661A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
KR20220132595A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 C3-치환된 1H-피라졸로[4,3-d]피리미딘 화합물 |
US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
BR112022024729A2 (pt) | 2020-06-05 | 2023-02-28 | Kinnate Biopharma Inc | Inibidores de quinases do receptor do fator de crescimento de fibroblastos |
JP2023536945A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途 |
CN114805392A (zh) * | 2021-01-20 | 2022-07-29 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
WO2022206752A1 (zh) * | 2021-03-29 | 2022-10-06 | 正大天晴药业集团股份有限公司 | Toll样受体7激动剂和抗PD-L1抗体的药物联合 |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN114409654A (zh) * | 2021-12-30 | 2022-04-29 | 安徽普利药业有限公司 | 一种btk抑制剂的中间体合成方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2230808C (en) | 1996-07-03 | 2006-08-15 | Japan Energy Corporation | A novel purine derivative |
EP1035123B1 (en) | 1997-11-28 | 2003-08-20 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
EP1931352B1 (en) * | 2005-08-22 | 2016-04-13 | The Regents of The University of California | Tlr agonists |
ES2552471T3 (es) * | 2007-02-07 | 2015-11-30 | The Regents Of The University Of California | Conjugados de agonistas de TLR sintéticos y usos de los mismos |
PT2170888E (pt) | 2007-06-29 | 2015-08-21 | Gilead Sciences Inc | Purina derivados e sua utilização como moduladores de recetor de tipo toll 7 |
ES2359123T3 (es) | 2007-08-03 | 2011-05-18 | Pfizer Limited | Imidazopiridinonas. |
NZ612380A (en) | 2008-12-09 | 2015-01-30 | Gilead Sciences Inc | Modulators of toll-like receptors |
DE102011008352A1 (de) * | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
CA2826295C (en) * | 2011-02-04 | 2020-10-20 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
EP2674170B1 (en) * | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
CN104837840B (zh) * | 2012-10-10 | 2017-08-08 | 爱尔兰詹森科学公司 | 用于治疗病毒感染及其他疾病的吡咯并[3,2‑d]嘧啶衍生物 |
BR112015011447A2 (pt) * | 2012-11-20 | 2017-07-11 | Glaxosmithkline Llc | composto da fórmula i, composição farmacêutica e de vacina, e, uso de um composto |
PE20151086A1 (es) * | 2012-11-20 | 2015-08-20 | Glaxosmithkline Llc | COMPUESTOS DERIVADOS DE 5H-PIRROLO-[3,2-d]PIRIMIDIN-4-AMINA 2,6,7 TRISUSTITUIDOS O 2,7 DISUSTITUIDOS COMO INDUCTORES DEL INTERFERON HUMANO |
CN104780923B (zh) * | 2012-11-20 | 2017-03-15 | 葛兰素史克有限责任公司 | 干扰素诱导剂化合物 |
AU2015220888B2 (en) | 2014-02-20 | 2017-05-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon |
BR112016025048A2 (pt) | 2014-05-01 | 2017-10-31 | Novartis Ag | compostos e composições como agonistas do receptor tipo toll7 |
KR102139847B1 (ko) | 2014-05-01 | 2020-07-31 | 노파르티스 아게 | 톨-유사 수용체 7 효능제로서의 화합물 및 조성물 |
CN110938076B (zh) * | 2014-08-15 | 2021-08-10 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
-
2015
- 2015-08-14 CN CN201911020774.XA patent/CN110938076B/zh active Active
- 2015-08-14 SI SI201531613T patent/SI3190113T1/sl unknown
- 2015-08-14 ES ES15831451T patent/ES2875313T3/es active Active
- 2015-08-14 UA UAA201702350A patent/UA117634C2/uk unknown
- 2015-08-14 LT LTEP15831451.8T patent/LT3190113T/lt unknown
- 2015-08-14 SG SG10201809918RA patent/SG10201809918RA/en unknown
- 2015-08-14 WO PCT/CN2015/086909 patent/WO2016023511A1/zh active Application Filing
- 2015-08-14 CN CN201580041989.3A patent/CN106661034B/zh active Active
- 2015-08-14 BR BR112017002811-5A patent/BR112017002811B1/pt active IP Right Grant
- 2015-08-14 MY MYPI2017700489A patent/MY190026A/en unknown
- 2015-08-14 AU AU2015303558A patent/AU2015303558B2/en active Active
- 2015-08-14 KR KR1020177007194A patent/KR102215609B1/ko active IP Right Grant
- 2015-08-14 PT PT158314518T patent/PT3190113T/pt unknown
- 2015-08-14 JP JP2017527961A patent/JP6328341B2/ja active Active
- 2015-08-14 CN CN201911022725.XA patent/CN110759916B/zh active Active
- 2015-08-14 SG SG11201701169XA patent/SG11201701169XA/en unknown
- 2015-08-14 KR KR1020197024042A patent/KR20190098277A/ko not_active Application Discontinuation
- 2015-08-14 EA EA201790389A patent/EA032824B1/ru unknown
- 2015-08-14 US US15/503,977 patent/US9962388B2/en active Active
- 2015-08-14 EP EP15831451.8A patent/EP3190113B1/en active Active
- 2015-08-14 DK DK15831451.8T patent/DK3190113T3/da active
- 2015-08-14 MX MX2017002028A patent/MX2017002028A/es unknown
- 2015-08-14 CN CN202110224402.XA patent/CN112898308A/zh active Pending
- 2015-08-14 HU HUE15831451A patent/HUE054672T2/hu unknown
- 2015-08-14 PL PL15831451T patent/PL3190113T3/pl unknown
- 2015-08-14 CA CA2958097A patent/CA2958097C/en active Active
-
2017
- 2017-02-14 IL IL250586A patent/IL250586B/en active IP Right Grant
- 2017-02-14 CL CL2017000379A patent/CL2017000379A1/es unknown
- 2017-02-15 PH PH12017500281A patent/PH12017500281B1/en unknown
-
2018
- 2018-04-17 US US15/955,523 patent/US10555949B2/en active Active
- 2018-04-17 JP JP2018079330A patent/JP6639551B2/ja active Active
- 2018-06-06 ZA ZA2018/03736A patent/ZA201803736B/en unknown
- 2018-10-01 AU AU2018236899A patent/AU2018236899B2/en active Active
-
2019
- 2019-10-22 AU AU2019253788A patent/AU2019253788C1/en active Active
-
2020
- 2020-07-16 PH PH12020551089A patent/PH12020551089A1/en unknown
- 2020-08-25 IL IL276908A patent/IL276908A/en unknown
-
2021
- 2021-06-09 HR HRP20210927TT patent/HRP20210927T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276908A (en) | Use of pyrrolopyrimidine compounds as an agonist for TLR7 | |
DK3436461T3 (da) | Pyrrolotriazinforbindelser som tam-inhibitorer | |
DK3277677T3 (da) | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere | |
DK3209656T3 (da) | Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere | |
DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
DK3105218T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
DK3105226T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
DK3294713T5 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
DK3235819T3 (da) | Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer | |
DK3288944T3 (da) | Imidazopyrazinoner som pde1-inhibitorer | |
DK3116475T3 (da) | Dopa-decarboxylasehæmmersammensætninger | |
DK3256462T3 (da) | Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel | |
DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
DK3177624T3 (da) | Imidazopyridazinforbindelser | |
BR112016030730A2 (pt) | Composto | |
BR112017013013A2 (pt) | combinações de composto ativo | |
DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
DK3212237T3 (da) | Methotrexatformulering | |
DK3597189T3 (da) | Krystallinske forbindelser | |
DK3319970T3 (da) | Pyrido-oxazinonderivater som tnap-hæmmere | |
DK3233862T3 (da) | Imidazopyridazinderivater som pi3k-beta-inhibitorer | |
DK3233839T3 (da) | Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer | |
DK3148513T3 (da) | Ceritinib-formulering | |
DK3126354T3 (da) | Halogenerede quinazolin-thf-aminer som pde1-inhibitorer | |
DK3193856T3 (da) | Formulering |